Home/Filings/4/0000899243-20-005958
4//SEC Filing

Thomson Peter G. 4

Accession 0000899243-20-005958

CIK 0001680581other

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 7:52 PM ET

Size

9.6 KB

Accession

0000899243-20-005958

Insider Transaction Report

Form 4
Period: 2020-02-24
Thomson Peter G.
See Remarks
Transactions
  • Sale

    Common Stock

    2020-02-24$16.18/sh2,648$42,85730,923 total
  • Sale

    Common Stock

    2020-02-24$18.61/sh250$4,65328,571 total
  • Sale

    Common Stock

    2020-02-24$17.43/sh2,102$36,64328,821 total
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.91, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.29 to $19.01, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother

Related Parties

1
  • filerCIK 0001779120

Filing Metadata

Form type
4
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 7:52 PM ET
Size
9.6 KB